Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17288933 | 0.69 | ADAMTS4 (0.32) | — | |
| SCHEMBL17289186 | 0.69 | — | — | |
| SCHEMBL7172036 | 0.67 | ABCG2 (0.40) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL452883 | 0.67 | — | — | |
| SCHEMBL17289110 | 0.66 | CA1 (0.38) | ABCG2 | |
| SCHEMBL451675 | 0.65 | TRPA1 (0.30) | — | |
| SCHEMBL17289161 | 0.65 | TRPA1 (0.40) | — | |
| SCHEMBL3557 | 0.64 | — | — | |
| SCHEMBL121647 | 0.64 | LMNA (0.43) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL30334802 | 0.64 | LMNA (0.43) | ABCG2ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023237097-A1 | 19-NOR-C3,3-DISUBSTITUTED C21-AZACYCLO-SUBSTITUTED STEROID AND METHOD FOR USING SAME | 山东绿叶制药有限公司 | 2023-12-14 | — | — | WO | claimed |
| EP-3409668-B1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2020-10-21 | — | — | EP | claimed |
| US-10781201-B2 | Benzimidazole derivative having JNK inhibitory activity and use thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2020-09-22 | — | — | US | claimed |
| US-20200039959-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2020-02-06 | — | — | US | claimed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | claimed |
| EP-3010906-B1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2019-06-12 | — | — | EP | claimed |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-05-28 | — | — | US | claimed |
| US-10280149-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | claimed |
| US-20190031645-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-31 | — | — | US | claimed |
| EP-3409668-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2018-12-05 | — | — | EP | claimed |
| US-5804586-A | ANALGESICS, PSYCHOLOGICAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-09-08 | — | — | US | claimed |
| WO-1998018757-A1 | SYNTHESIS OF BENZO[F]QUINOLINONES | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0707570-B1 | ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1998-05-06 | — | — | EP | claimed |
| EP-0839807-A1 | Synthesis of benzo(f)quinolinones | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0707570-A1 | ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-04-24 | — | — | EP | claimed |
| EP-0656885-A1 | SYNTHESIS OF 2-SUBSTITUTED QUINAZOLINE COMPOUNDS (SUCH AS TERAZOSIN) AND MEOBENTINE AND BETHANIDINE AND INTERMEDIATES THEREFOR | ACIC (CANADA) INC. (CA) | 1995-06-14 | — | — | EP | claimed |
| WO-1995000489-A1 | ISOQUINOLINE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | claimed |
| WO-1994005628-A1 | SYNTHESIS OF 2-SUBSTITUTED QUINAZOLINE COMPOUNDS (SUCH AS TERAZOSIN) AND MEOBENTINE AND BETHANIDINE AND INTERMEDIATES THEREFOR | ACIC (CANADA) INC. (CA) | 1994-03-17 | — | — | WO | claimed |
| EP-0114850-B1 | NEW SUBSTITUTED DERIVATIVES OF 2,5-DIAMINO 1,4-DIAZOLE, PREPARATION METHODS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOUCHARA S.A. (FR) | 1988-06-29 | — | — | EP | claimed |
| US-4569933-A | Antihypertensive substituted derivatives of 2,5-diamino 1,4-diazole | CORNU PIERRE JEAN | 1986-02-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031645-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | MAPKAPK2, MAPKAPK3, MAP3K7 | ABCG2 2469/4885ITGB2 4768/4885ICAM1 1380/4885 |
| US-10301291-B2 | Imidazole derivative having JNK inhibitory activity and use thereof | MAPKAPK2, MAPKAPK3, MAP3K7 | ABCG2 2305/4885ITGB2 4776/4885ICAM1 1073/4885 |
| US-10280149-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | ABCG2 4006/4885ITGB2 3670/4885ICAM1 3260/4885 |
| US-20200039959-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF | MAPKAPK3, MAPK3, MAP3K3 | ABCG2 2556/4885ITGB2 4649/4885ICAM1 2478/4885 |
| US-10781201-B2 | Benzimidazole derivative having JNK inhibitory activity and use thereof | MAPKAPK3, MAPK3, MAP3K3 | ABCG2 2298/4885ITGB2 4623/4885ICAM1 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.